Loading...
This comprehensive guideline updates and consolidates a 2013 multisociety guideline on management of heart failure (HF) and a 2017 update. Recommendations encompass prevention, evaluation, and treatment in patients with heart failure from stages A (at risk for HF) to D (advanced HF).
More-aggressive use of sodium–glucose cotransporter-2 (SGLT-2) and angiotensin receptor–neprilysin inhibitors (ARNIs) is recommended, including use of SGLT-2 inhibitors for HF with preserved ejection fraction. Atrial fibrillation (AF) management is more fully addressed with anticoagulation and a rhyth…